The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This research is being done to study the effects of the drug omalizumab (Xolair) in people
with cat allergies. The investigators will use omalizumab to study changes in the cells in
the nose, cells in the blood and cells in the skin that cause allergies. The investigators
will compare the changes in the nose to changes in the skin and blood cells.
Objective: To test the hypothesis that treatment with omalizumab will decrease the nasal
allergen challenge late-phase eosinophil count in nasal brushings at the time when blood
basophils have become hypo-responsive to in vitro allergen exposure.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Genentech, Inc. National Institute of Allergy and Infectious Diseases (NIAID)